Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021
Catalyst Pharmaceuticals (Nasdaq: CPRX) will release its Q1 2021 financial results after market close on May 10, 2021. A conference call is scheduled for May 11, 2021, at 8:30 a.m. ET to discuss the results and provide corporate updates. Catalyst focuses on developing high-quality medicines for rare diseases, with Firdapse® (amifampridine) currently being evaluated for MuSK-MG and recently approved in Canada for LEMS. The company is committed to a robust pipeline of medicines and maintains transparency regarding known risks in its forward-looking statements.
- Scheduled Q1 2021 earnings release may attract investor interest.
- Firdapse® has been commercially available in the U.S. since 2018 and is now approved in Canada, expanding its market.
- Forward-looking statements include risks and uncertainties that could adversely affect Catalyst's future results.
CORAL GABLES, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release first quarter 2021 financial results after market close on Monday, May 10, 2021. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Tuesday, May 11, 2021 to discuss the financial results and to provide a corporate update.
Investors who wish to participate in the conference call may do so by dialing (877) 407-8912 for domestic and Canadian callers or (201) 689-8059 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the company's website at www.catalystpharma.com and clicking on the webcast link on the Investors home page.
A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and Firdapse® is commercially available in the United States. Further, Canada’s national healthcare regulatory agency, Health Canada, recently approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with LEMS.
Firdapse® is currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2020 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
FAQ
When will Catalyst Pharmaceuticals release its Q1 2021 financial results?
What is the date of the conference call for Catalyst Pharmaceuticals' Q1 2021 results?
What is Firdapse® and its significance for Catalyst Pharmaceuticals?
What are the known risks associated with Catalyst Pharmaceuticals as mentioned in the press release?
